Lineage Cell Therapeutics, Inc announced that Renevia has been granted a CE Mark for the treatment of facial lipoatrophy,
Lineage Cell Therapeutics, Inc announced that Renevia, the Company�s facial aesthetics product, has been granted a Conformit� Europ�enne (CE) Mark. Renevia received a Class III classification with an intended use in adults as a resorbable matrix for the delivery of autologous adipose tissue preparations to restore and/or augment facial volume after subcutaneous fat volume loss for the treatment of facial lipoatrophy.
The CE Mark provides Lineage, or its authorized agent, the authority to market and distribute Renevia throughout the European Union (EU) and in other countries that recognize the CE Mark.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.